{"id":{"repo_id":"buffalo","oai_identifier":"oai:ubir.buffalo.edu:10477/86440"},"canonical_url":"https://search.dev.ndltd.org/etd/buffalo/oai:ubir.buffalo.edu:10477/86440","repository":{"repo_id":"buffalo","name":"Buffalo","base_url":"https://ubir.buffalo.edu/oai/request"},"display":{"title":"Developing Immunomodulatory Nanocarriers for the treatment of Myocardial Infarction","abstract":"Ph.D.","abstract_html":"Ph.D.","abstract_has_math":false,"creators":["Wang, Jinli"],"institution":"State University of New York at Buffalo","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Nguyen, Juliane","Biomedical Engineering"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025-02-21T17:22:27Z","date_published":"2025-02-21T17:22:27Z","updated_at":"2026-07-27T19:05:32Z","subjects":["biomedical engineering"],"languages":["eng"],"rights":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10477/86440","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Nguyen, Juliane","Biomedical Engineering"]},{"key":"dc:creator","label":"Author","values":["Wang, Jinli"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2025-02-21T17:22:27Z","2020"]},{"key":"dc:publisher","label":"Institution","values":["State University of New York at Buffalo"]},{"key":"dc:type","label":"Dc Type","values":["Text","Dissertation"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["biomedical engineering"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/10477/86440"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Ph.D.","Myocardial infarction is the leading cause of death worldwide. Although reperfusion therapy restores blood flow to the ischemic myocardium and limits infarct size, it can cause additional damage to the ischemic heart, which is also known as reperfusion injury. Angiotensin-converting-enzyme inhibitors (ACEI) and beta-blockers play a key role in reducing the mortality rate of MI, however, there is no evidence that they can improve heart function. Due to the high economic and societal burden of MI, new therapies are urgently needed. Inflammation has been implicated in playing a central role in heart remodeling post MI. The inflammation response is mediated by a dynamic and sequential infiltration of inflammatory cells after MI. Although inflammation is integral to cardiac healing after MI, accumulating evidence suggests that dysregulated inflammation leads to deteriorative remodeling and subsequently heart failure. Modulating the immune response by targeting inflammatory cells and cytokines provides a promising platform for the treatment of cardiovascular diseases. To decrease toxic side effects of drugs, enhance specific targeting, and obtain controlled drug release, researchers have been developing nanotechnology-based drug delivery systems for the treatment of cardiovascular diseases. Both synthetic nanoparticles (NPs) and natural biocarriers have been reported to successfully deliver molecules with specific biological activity to the ischemic heart.","**To request an accessible version of the file(s) associated with this item, contact library@buffalo.edu. Please include the item's persistent URL [http://hdl.handle.net/. . .] in your request.**"]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Developing Immunomodulatory Nanocarriers for the treatment of Myocardial Infarction"]}]}],"canonical_facts":{"dc:contributor":["Nguyen, Juliane","Biomedical Engineering"],"dc:creator":["Wang, Jinli"],"dc:date":["2025-02-21T17:22:27Z","2020"],"dc:description":["Ph.D.","Myocardial infarction is the leading cause of death worldwide. Although reperfusion therapy restores blood flow to the ischemic myocardium and limits infarct size, it can cause additional damage to the ischemic heart, which is also known as reperfusion injury. Angiotensin-converting-enzyme inhibitors (ACEI) and beta-blockers play a key role in reducing the mortality rate of MI, however, there is no evidence that they can improve heart function. Due to the high economic and societal burden of MI, new therapies are urgently needed. Inflammation has been implicated in playing a central role in heart remodeling post MI. The inflammation response is mediated by a dynamic and sequential infiltration of inflammatory cells after MI. Although inflammation is integral to cardiac healing after MI, accumulating evidence suggests that dysregulated inflammation leads to deteriorative remodeling and subsequently heart failure. Modulating the immune response by targeting inflammatory cells and cytokines provides a promising platform for the treatment of cardiovascular diseases. To decrease toxic side effects of drugs, enhance specific targeting, and obtain controlled drug release, researchers have been developing nanotechnology-based drug delivery systems for the treatment of cardiovascular diseases. Both synthetic nanoparticles (NPs) and natural biocarriers have been reported to successfully deliver molecules with specific biological activity to the ischemic heart.","**To request an accessible version of the file(s) associated with this item, contact library@buffalo.edu. Please include the item's persistent URL [http://hdl.handle.net/. . .] in your request.**"],"dc:format":["application/pdf"],"dc:identifier":["http://hdl.handle.net/10477/86440"],"dc:language":["eng"],"dc:publisher":["State University of New York at Buffalo"],"dc:rights":["Users of works found in University at Buffalo Institutional Repository (UBIR) are responsible for identifying and contacting the copyright owner for permission to reuse. University at Buffalo Libraries do not manage rights for copyright-protected works and cannot assist with permissions.","Copyright retained by author."],"dc:subject":["biomedical engineering"],"dc:title":["Developing Immunomodulatory Nanocarriers for the treatment of Myocardial Infarction"],"dc:type":["Text","Dissertation"]},"updated_at":"2026-07-27T19:05:32Z"}